Pharmacokinetics
Pharmacokinetics is the science of measuring what happens to a compound over time in a study — how its levels rise, spread, break down, and clear in the test system being observed.
Where the word comes from
From Greek pharmakon, “drug,” plus kinētikos, “of motion” — literally “the movement of a compound through a system.” Ancient Greek pharmakon was a broad word that covered drugs, remedies, and poisons alike. The compound term entered scientific use in the mid-1900s, when researchers began describing measured rise-and-fall curves with mathematics.
What it means here
Published papers often report pharmacokinetic data, such as a half-life or a peak concentration. These numbers describe measurements from one specific study in one specific model, and they do not transfer between settings. When a page on our site mentions pharmacokinetics, it is summarizing what a cited study measured — context from the research record, never guidance. It is one of the clearest examples of a term where the honest register is simply reporting.
Words you’ll see together
- half-life — the best-known pharmacokinetic number, reported as a study measurement
- plasma half-life — the same measurement made from blood samples collected in a study
- clearance — how quickly a compound is removed from the test system, measured in a study
- elimination — the clearing phase of a study’s measured curve
Related terms
- Half-life — the best-known pharmacokinetic measurement
- Preclinical — the lab and animal studies where much of this data comes from
- Clinical trial phases — early phases collect this kind of measurement in humans
- Peptide — the class of molecule these studies measure on our pages
Where it appears in our catalog
- CJC-1295 DAC — published Phase 1 pharmacokinetic data is part of its research record
- Tirzepatide — a compound with an extensive published trial record
- Comparing compounds — why measured study properties differ across compounds
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 91(3):799-805. PMID: 16352683
